VKTX 8-K 2026-09-28
Viking Therapeutics, Inc. (VKTX) 8-K dated 2026-09-28 — accession 0001193125-26-405580.
Viking Therapeutics, Inc. (VKTX) is a biotechnology company listed on US.
Viking Therapeutics, Inc. filed a 8-K on 2026-09-28. Accession 0001193125-26-405580.
This 8-K covers: Material agreement (Item 1.01), New debt obligation (Item 2.03), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported VKTX revenue for 2025-12-31 was $0. Net income was -$359.6M. VKTX currently screens at market cap $3.97B.
Not investment advice. The VKTX SEC hub lists recent forms. The stock page is the research view.